Abstract
This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].
Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.
Current Drug Targets
Title:Pharmacokinetics in IBD: Ready for Prime Time?
Volume: 15 Issue: 11
Author(s): Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque and Stephane Paul
Affiliation:
Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.
Abstract: This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].
Export Options
About this article
Cite this article as:
Roblin Xavier, Rinaudo Melanie, Sparrow Peter Miles, Moreau Amelie, Phelip Marc Jean, Genin Christian, Lamarque Dominique and Paul Stephane, Pharmacokinetics in IBD: Ready for Prime Time?, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140829153509
DOI https://dx.doi.org/10.2174/1389450115666140829153509 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory and Antimicrobial Effects of Flavonoids from Heliotropium ellipticum Exudate
Current Bioactive Compounds Fluorescence Detection of MMP-9. I. MMP-9 Selectively Cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys Peptide
Current Pharmaceutical Biotechnology Gold - Old Drug with New Potentials
Current Medicinal Chemistry The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research Monoclonal Antibodies - Regulatory Challenges
Current Pharmaceutical Biotechnology Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Current Drug Targets The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Editorial
Current Radiopharmaceuticals Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Calcium Intake Requirements Along the Life Cycle and Associated Factors
Current Nutrition & Food Science Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Evaluation of Anticancer Activities of Gallic Acid and Tartaric Acid Vectorized on Iron Oxide Nanoparticles
Drug Delivery Letters Chemokines in Rheumatic Diseases
Current Drug Targets